Comparison of Blood Biochemical Levels in NCDs Patients Receiving Anti-infective Novel Coronavirus Disease-2019 Drugs, Map Ta Phut District, Rayong Province เปรียบเทียบระดับสารชีวเคมีในเลือดของผู้ป่วยโรคไม่ติดต่อเรื้อรังที่ได้รับยาต้านการติดเชื้อไวรัสโคโรนาสายพันธุ์ใหม่ 2019 เขตมาบตาพุด จังหวัดระยอง
Article Sidebar
Main Article Content
Abstract
The novel coronavirus disease-2019 (COVID-19) infection causing the patient to need medicine treatment and may affect the biochemical level with non-communicable diseases (NCDs) patients. This descriptive study aimed to compare blood biochemical levels receiving anti-infective corona virus disease 2019 drugs, Map Ta Phut District, Rayong Province. The sample were 92 patients. Data were collected by interviews and blood biochemical tests including fasting blood sugar, white blood cells, low density lipoprotein, high density lipoprotein, cholesterol, and triglycerides. The patients were examined twice: before and after receiving anti-infective drugs. The descriptive statistics such as number, percentage, mean, standard deviation, minimum, maximum and inferential statistics such as Wilcoxon Signed Ranks test were analyzed data.
Results showed that mostly female patients were 73.9 %, with a mean age of 53.0±17.5 years and a body mass index of 25.3±6.2 kg/m2. The patient's occupation is farming gardening and general labor was 60.9 %, did not smoke and drank alcohol was 95.7 and 80.2 % respectively. There was no difference in biochemical parameters between NCDs infected with COVID-19 before and after receiving anti-infective drugs. However, the percentage change in blood glucose was reduced by 10.2%, while low density lipoprotein and cholesterol increased by 4.0% and 2.8%, respectively. The study's data can be used as a guideline for hospitals to monitor patients with NCDs infected with COVID-19; in particular, people with pre-existing diabetes mellitus should be monitored for symptoms or assessed for hypoglycemia to prevent treatment complications.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Palmer K, Monaco A, Kivipelto M, Onder G, Maggi S, Michel JP, Prieto R, Sykara G, Donde S. The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: Consequences for healthy ageing. Aging Clinical and Experimental Research 2020;32:1189-1194.
World Health Organization (WHO). Coronavirus (COVID-19) dashboard, Global situation [Internet]. 2021. [cited 29 December 2021]. Available from: https:22covid19.who.int/
กองโรคไม่ติดต่อ. ผลกระทบของ COVID-19 ต่อระบบบริการโรคไม่ติดต่อเรื้อรัง. นนทบุรี: กรมควบคุมโรค กระทรวง สาธารณสุข; 2564.
Horton, R. (Editorial). COVID-19: a new lens for non-communicable diseases. Lancet Glob Health, 8, e1003.
World Health Organization (WHO). SAGE roadmap for prioritizing used of COVID-19 vaccines in the context of limited supply [Internet]. 2021. [cited 25 December 2021].Available from: https://www.who.int/publications/i/item/ who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply
Kim SR, Nam SH, Kim YR. Risk Factors on the Progression to Clinical Outcomes of COVID-19 Patients in South Korea: Using National Data. Int J Environ Res Public Health 2020;17(23): 8847.
Tian T, Zhang J, Hu L, Jiang Y, Duan C, Li Z, Wang X, Zhang H. Risk factors associated with mortality of COVID-19 in 3125 counties of the United States. Infectious Diseases of Poverty. [Internet]. 2021. [cited 21 December 2021]. Available from: https://doi.org/10.1186/s40249-020-00786-0
กรมการแพทย์. แนวทางเวชปฏิบัติ การวินิจฉัย ดูแลรักษา และป้องกันการติดเชื้อในโรงพยาบาล กรณีโรคติดเชื้อไวรัสโคโรนา 2019 (COVID-19). ฉบับปรับปรุง วันที่ 1 พฤษภาคม พ.ศ. 2563 สำหรับแพทย์และบุคลากรสาธารณสุข [อินเทอร์เน็ต]. 2564. [เข้าถึงเมื่อ 26 ธันวาคม 2564] เข้าถึงได้จาก: https://covid19.dms.go.th/ Content/ Select_Landding_ page?contentId=69
Khan EA, Hoque MM, Mallik MU, Basu KC, Hasan MM, Mahmud I, Adnan MMA, Rahman MM. Favipiravir induced acute pancreatitis in a COVID-19 patient. J Medicine 2021; 22: 69-71.
Nakamura H, Miyagi K, Otsuki M, Higure Y, Nishiyama N, Kinjo T, Nakamatsu M, Haranaga S, Tateyama M, Fujita J. Acute hypertriglyceridaemia caused by tocilizumab in a patient with severe COVID-19. Intern Med Advance Publication 2021. doi: 10.2169/internalmedicine. 5244 – 20.
กรมควบคุมโรค. โรคติดเชื้อไวรัสโคโรนา 2019 (COVID-19) สถานการณ์ในประเทศไทย [อินเทอร์เน็ต]. 2565. [เข้าถึงเมื่อ 13 มีนาคม 2565] เข้าถึงได้จาก: https://ddc.moph.go.th/viralpneumonia/eng/index.php
Baker MG, Peckham TK, Seixas NS. Estimating the burden of United States workers exposed to infection or disease: A key factor in containing risk of COVID-19 infection. PLoS ONE. [Internet]. 2020. [cited 25 December 2021]. Available from: https://doi.org/10.1371/journal.pone.0232452
พรรษมน โพธิ์ผ่าน. ความรู้สู่ประชาชน: เม็ดเลือดขาวต่ำเกิดจาดอะไร. สมาคมโลหิตวิทยาแห่งประเทศไทย [อินเทอร์เน็ต]. 2564. [เข้าถึงเมื่อ 26 ธันวาคม 2564] เข้าถึงได้จาก:http://tsh.or.th/Knowledge/Details/83
Yaylaci S, Dheir H, Senocak D, Genc AB, Kocayigit H, Cekic D, et al. The effects of favipiravir on hematological parameters of covid-19 patients. REV ASSOC BRAS 2020;66:65-70.
Topaloglu US, Eren E, Serkan Y. Management of Type 2 Diabetes Mellitus in a Patient with COVID- 19: The Window of Insulin Glargine U300/COVID-19 Olan Bir Hastada Tip 2 Diabetes Mellitus Yonetimi: Insulin Glarjin U300 Penceresi [Internet]. 2021. [cited 29 December 2021]. Available from: Health and Medicine link.gale.com/apps/doc/A675821394/HRCA?u=anon~fc9808fd&sid=
googleScholar&xid=3991e6c7.
Sood S, Bhatia GK, Seth P, Kumar P, Gupta V, Punia S, Tuli S. Efficacy and safety of new and emerging drugs for COVID-19: Favipiravir and Dexamethadone. Current Pharmacology Reports 2021;7:49-54.
Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The effectiveness and safety of Favipiravir in COVID-19 hospitalized patients at Tertiary Referral hospital, Bali, Indonesia. National Public Health Journal 2021; 16: 289-297.
Hu X, Chen D, Wu L, He G, Ye W. Low serum cholesterol level among patients with COVID-19 infection in Wenzhou, China. SSRN Electron. J. [Internet]. 2020. [cited 7 January 2022]. Available from: https:// doi.org/10.2139/ssrn.3544826
Zaki N, Alashwal H, Ibrahim S. (2020). Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2020; 14: 1133-1142.